Viewing Study NCT05243693


Ignite Creation Date: 2025-12-25 @ 1:06 AM
Ignite Modification Date: 2026-01-01 @ 10:32 PM
Study NCT ID: NCT05243693
Status: RECRUITING
Last Update Posted: 2022-02-17
First Post: 2022-01-02
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma
Sponsor: National Cancer Center, Korea
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module